Effects of levosimendan on hemodynamics and cardiac function in patients with septic shock

Chinese Critical Care Medicine

Volumn 26, Issue 10, 2014, Pages 692-696

  Fang, Mingxing ^a   Dong, Shimin ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Dobutamine; Heart failure; Levosimendan; Septic shock

Indexed keywords

HYDRAZONE DERIVATIVE; NORADRENALIN; PYRIDAZINE DERIVATIVE; SIMENDAN; DOBUTAMINE; LACTIC ACID; LEVOSIMENDAN;

CENTRAL VENOUS PRESSURE; CONTROLLED STUDY; DRUG EFFECTS; FLUID THERAPY; HEART OUTPUT; HEART STROKE VOLUME; HEMODYNAMICS; HUMAN; LUNG EXTRAVASCULAR FLUID; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SHOCK, SEPTIC; TREATMENT OUTCOME; ARTICLE; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG MECHANISM; ECHOCARDIOGRAPHY; EXTRAVASCULAR LUNG WATER INDEX; FLUID RESUSCITATION; HEART FUNCTION; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE STROKE WORK INDEX; INTENSIVE CARE UNIT; INTRACARDIAC ECHOCARDIOGRAPHY; INTRATHORACIC BLOOD VOLUME INDEX; LACTATE BLOOD LEVEL; MORTALITY; PLASMA CLEARANCE; SEPTIC SHOCK; URINE VOLUME;

CARDIAC OUTPUT; CENTRAL VENOUS PRESSURE; EXTRAVASCULAR LUNG WATER; FLUID THERAPY; HEMODYNAMICS; HUMANS; HYDRAZONES; NOREPINEPHRINE; PROSPECTIVE STUDIES; PYRIDAZINES; SHOCK, SEPTIC; STROKE VOLUME; TREATMENT OUTCOME;

EID: 84908661998     PISSN: 10030603     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.2095-4352.2014.10.002     Document Type: Article

References (11)

1. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008 [J]. Crit Care Med, 2008, 36 (1):296-327.
2. Sorsa T, Pollesello P, Solaro RJ. The contractile apparatus as a target for drugs against heart failure interaction of levosimendan, a calciumsensitiser, with cardiac troponin c [J]. Mol Cell Biochem, 2004, 266 (1-2) 87-107
3. Hollenberg SM, Ahrens TS, Annane D, et al. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update [J]. Crit Care Med, 2004, 32 (9): 1928-1948
4. Haikala H, Kaivola J, Nissinen E, et al. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan [J]. J Mol Cell Cardiol, 1995, 27 (9): 1 859-1866.
5. Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure:the Task Force on Acute Heart Failure of the European Society of Cardiology [J]. Eur Heart J, 2005, 26 (4): 384-416.
6. Sorsa T, Pollesello P, Rosevear PR, et al. Stereoselective binding of levosimendan to cardiac troponin C causes Ca2+-sensitization [J]. Eur J Pharmacol, 2004, 486 (1) 1-8.
7. Morelli A, De Castro S, Teboul JL, et al. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression [J]. Intensive Care Med, 2005, 3 ((5): 638-644.
8. Morelli A, Teboul JL, Maggiore SM, et al. Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome a pilot study [J]. Crit Care Med, 2006, 34 (9) 2287-2293.
9. Yokoshiki H, Katsube Y, Sunagawa M, et al. The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells [J]. J Pharmacol Exp Ther, 1997, 283 (1) 375-383.
10. Toller WG, Stranz C. Levosimendan, a new inotropic and vasodilator agent [J]. Anesthesiology, 2006, 104 (3):556-569.
11. Yildiz O. Vasodilating mechanisms of levosimendan: involvement of K+ channels [J]. J Pharmacol Sci, 2007, 104 (1): 1-5.